Further experiments are required to test whether treatment with AAV9-Chrdl1 could reverse established fibrosis, for example, by administering Chrdl1 at 4 weeks after MI when mature fibrotic scars form in this model and test the effects on cardiac function. This evidence concerns the gene CHRDL1 and myocardial infarction.